2023
Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
Böhme T, Zeller T, Shishehbor M, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh S, Kashyap V, Pietras C, Tirziu D, Beschorner U, Krishnan P, Niazi K, Wali A, Lansky A. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. Journal Of Endovascular Therapy 2023, 15266028231179589. PMID: 37314243, DOI: 10.1177/15266028231179589.Peer-Reviewed Original ResearchLutonix drug-coated balloonDrug-coated balloonsPrimary safety endpointDM statusFemoropopliteal diseaseDiabetes mellitusSafety endpointFemoropopliteal lesionsSimilar safetyHigh-risk patient populationFemoropopliteal artery lesionsIschemic rest painNon-DM patientsSymptomatic femoropopliteal lesionsPrimary efficacy endpointMajor adverse eventsTherapy of choiceDrug-Coated BalloonMajor amputationRest painEfficacy endpointPrimary patencyAdverse eventsArtery lesionsDiabetes status
2022
Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Cequier Á, Takahashi A, Cannon L, Amoroso G, Kakuta T, Saito S, Leon M, Lansky A. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100033. PMID: 39132558, PMCID: PMC11307809, DOI: 10.1016/j.jscai.2022.100033.Peer-Reviewed Original ResearchTarget vessel myocardial infarctionVessel myocardial infarctionDiabetes mellitusDP-EESLesion failureIII trialsCardiac deathMyocardial infarctionBiodegradable Polymer Sirolimus-Eluting StentBiodegradable polymer sirolimus-eluting stentsTarget lesion failureTarget lesion revascularizationPercutaneous coronary interventionSirolimus-Eluting StentsLong-term inflammatory responseDiabetic subgroupsLesion revascularizationNondiabetic patientsSecondary endpointsBackground PatientsCoronary interventionPrespecified analysisComposite endpointPrimary safetyWorse outcomes
2021
TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial
Thomas A, Kereiakes D, Leon M, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, Mclaurin B, Cequier A, Takahashi A, Amoroso G, Kakuta T, Carney R, Saito S, Lansky A. TCT-290 Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus: Results From the PIONEER III Clinical Trial. Journal Of The American College Of Cardiology 2021, 78: b119. DOI: 10.1016/j.jacc.2021.09.1143.Peer-Reviewed Original ResearchAtrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence
Vrachatis DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, Raisakis K, Iliodromitis KE, Reimers B, Stefanini GG, Cleman M, Sianos G, Lansky A, Deftereos SG, Giannopoulos G. Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research And Clinical Practice 2021, 174: 108724. PMID: 33647332, DOI: 10.1016/j.diabres.2021.108724.Peer-Reviewed Original ResearchConceptsDiabetes mellitusAtrial fibrillationType 1 diabetes mellitusIndependent risk factorAtrial fibrillation managementAtrial fibrillation riskAF developmentInsulin deficiencyGlycemic variabilityRisk factorsClinical dataClinical studiesMicrovascular sequelaeAtrial arrhythmogenesisAnimal studiesAtrial myocytesClinical practiceArrhythmia initiationStructural remodelingClinical implicationsT1DMOxidative stressPI3KGlucose transportationMellitus
2016
TCT-94 Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study
Kedhi E, Kennedy M, Maehara A, Lansky A, McAndrew T, Marso S, De Bruyne B, Serruys P, Stone G. TCT-94 Impact of Thin-Cap Fibroatheromas on Unanticipated Ischemic Events in Medically Treated Patients With Diabetes Mellitus: Insights From the PROSPECT Study. Journal Of The American College Of Cardiology 2016, 68: b38-b39. DOI: 10.1016/j.jacc.2016.09.359.Peer-Reviewed Original ResearchImpact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study
Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study. JACC Cardiovascular Imaging 2016, 10: 451-458. PMID: 27372016, DOI: 10.1016/j.jcmg.2015.12.023.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDiabetes MellitusDisease ProgressionFemaleFibrosisHumansMaleMiddle AgedPercutaneous Coronary InterventionPlaque, AtheroscleroticPredictive Value of TestsPropensity ScoreRisk FactorsRupture, SpontaneousTime FactorsTreatment OutcomeUltrasonography, InterventionalConceptsMajor adverse cardiac eventsAcute coronary syndromeThin-cap fibroatheromaNonculprit lesionsDiabetes mellitusACS patientsDM patientsSubsequent major adverse cardiac eventsPresence of DMPROSPECT studyAdverse cardiac eventsPropensity-matched groupsRadiofrequency intravascular ultrasoundHigh rateCoronary syndromeCardiac eventsPlaque compositionIntravascular ultrasoundPatientsPropensity scoreBalanced groupsIschemicMellitusFibroatheromaPrognosisSafety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2012
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial
Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial. American Heart Journal 2012, 165: 234-240.e1. PMID: 23351827, PMCID: PMC4637940, DOI: 10.1016/j.ahj.2012.10.023.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLate lossCoronary interventionDiabetes mellitusPrimary efficacy end pointBare metal stent implantationEnd pointSystemic innate immunityEfficacy end pointPlacebo-controlled trialPrimary end pointAcute coronary syndromeStent late lossMetal stent implantationSingle intravenous bolusVascular injury sitesAverage late lossBaseline monocyteLiposomal alendronateCoronary syndromePlacebo groupStudy drugCoronary narrowingOverall cohortPrespecified subgroupsRefining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment options
2011
Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction
Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, Mehran R, Stone GW. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. Circulation Cardiovascular Interventions 2011, 4: 130-138. PMID: 21364152, DOI: 10.1161/circinterventions.110.960245.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsTarget lesion revascularizationBare metal stentsHORIZONS-AMI trialDiabetic patientsDiabetes mellitusStent thrombosisMyocardial infarctionPercutaneous interventionIschemia-driven target lesion revascularizationMetal stentsAcute Myocardial Infarction trialHigh-risk diabetic patientsMyocardial Infarction trialPrimary percutaneous interventionInsulin-treated diabetesAcute myocardial infarctionAngiographic late lossComparable safety outcomesBinary restenosisHarmonizing OutcomesLesion revascularizationNondiabetic patientsAngiographic restenosis
2010
Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, Mehran R. Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up 2-Year Insights From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2010, 56: 1597-1604. PMID: 20888162, DOI: 10.1016/j.jacc.2010.08.608.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPaclitaxel-eluting stentsBare metal stentsDrug-eluting stentsElevation myocardial infarctionRisk factorsMyocardial infarctionClinical benefitVersus Bare-Metal StentsAbsolute incremental benefitHORIZONS-AMI trialBaseline risk factorsReference vessel diameterAngiographic Follow-upAbsolute treatment effectLesion revascularizationTLR proceduresTLR rateDiabetes mellitusIndependent predictorsRisk strataFollow-upRisk groupsHigh riskAntirestenotic properties
2009
SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease
Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GW. SPIRIT IV trial design: A large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. American Heart Journal 2009, 158: 520-526.e2. PMID: 19781409, DOI: 10.1016/j.ahj.2009.07.025.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsTarget lesion revascularizationCoronary artery diseaseSPIRIT IVLesion revascularizationArtery diseaseDiabetes mellitusIschemia-driven target lesion revascularizationNovo native coronary artery lesionsMajor adverse cardiac eventsNative coronary artery diseaseNative coronary artery lesionsTarget vessel myocardial infarctionEnd pointUS clinical sitesAdverse cardiac eventsPrimary end pointTarget lesion failureTarget vessel failureVessel myocardial infarctionCoronary artery lesionsReference vessel diameterClinical end pointsMulticenter clinical trialAngiographic late loss
2007
Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation
Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, Mehran R. Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation. Journal Of The American College Of Cardiology 2007, 50: 2111-2116. PMID: 18036446, DOI: 10.1016/j.jacc.2007.06.056.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stentsBare metal stentsSegment binary restenosisBinary restenosisClinical outcomesMajor adverse cardiac eventsSirolimus-Eluting Stent ImplantationAdverse cardiac eventsOutcomes of patientsTarget vessel revascularizationCongestive heart failureOutcomes of womenPercutaneous coronary interventionOverall clinical outcomeGender-specific differencesVessel revascularizationCardiac eventsCoronary interventionAngiographic featuresDiabetes mellitusHeart failureIndependent predictorsMultivariable analysisClinical benefitStent implantationComparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial)
Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW. Comparison of Myocardial Reperfusion in Patients Undergoing Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction With Versus Without Diabetes Mellitus (from the EMERALD Trial). The American Journal Of Cardiology 2007, 100: 206-210. PMID: 17631071, DOI: 10.1016/j.amjcard.2007.02.080.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionElevation myocardial infarctionPrimary PCIMyocardial blush gradeCongestive heart failurePercutaneous coronary interventionMyocardial infarctionNondiabetic patientsDiabetes mellitusInfarct sizeMyocardial perfusionBlush gradeCoronary interventionHeart failureMyocardial reperfusionDiabetic patientsAcute ST-segment elevation myocardial infarctionST-segment elevation acute myocardial infarctionFinal myocardial blush gradeVersus Without Diabetes MellitusElevation acute myocardial infarctionSevere congestive heart failureDistal embolic protectionFinal infarct size
2006
Volumetric Intravascular Ultrasound Assessment of Neointimal Hyperplasia and Nonuniform Stent Strut Distribution in Sirolimus-Eluting Stent Restenosis
Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, Costa JR, Tanaka K, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Volumetric Intravascular Ultrasound Assessment of Neointimal Hyperplasia and Nonuniform Stent Strut Distribution in Sirolimus-Eluting Stent Restenosis. The American Journal Of Cardiology 2006, 98: 1559-1562. PMID: 17145209, DOI: 10.1016/j.amjcard.2006.07.030.Peer-Reviewed Original ResearchConceptsMinimum lumen siteStent restenotic lesionsStent areaDiabetes mellitusLumen areaRestenotic lesionsStent strut distributionIH areaMinimal lumen area siteSirolimus-eluting stent implantationVolumetric intravascular ultrasound analysisIntravascular ultrasound assessmentMinimum stent areaIntravascular ultrasound analysisMinimum lumen areaMinimal lumen areaMinimal lumen siteIH responseSES implantationStent implantationUltrasound assessmentStent lengthNeointimal hyperplasiaStent restenosisStrut distributionA Prospective Registry to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Using the “Crush Technique”
Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, Trubelja N, Carlier SG, Mehran R, Dangas GD, Weisz G, Kreps EM, Collins M, Stone GW, Moses JW. A Prospective Registry to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Using the “Crush Technique”. The American Journal Of Cardiology 2006, 97: 1317-1321. PMID: 16635603, DOI: 10.1016/j.amjcard.2005.11.072.Peer-Reviewed Original ResearchConceptsSirolimus-eluting stentsCoronary bifurcation lesionsFinal kissing balloon inflationBifurcation lesionsKissing balloon inflationCrush techniqueBalloon inflationHigh procedural success rateLong-term clinical outcomesStent minimum lumen diameterSmaller reference diameterProcedural success rateExcellent patency ratesSide branch lesionsLong-term efficacyMinimum lumen diameterComplex bifurcation lesionsMain vesselSide branch ostiumBifurcation stenting techniquesLesion revascularizationNoncardiac causesProspective registryPatient ageDiabetes mellitus
2005
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction
Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. Journal Of The American College Of Cardiology 2005, 45: 508-514. PMID: 15708696, DOI: 10.1016/j.jacc.2004.10.054.Peer-Reviewed Original ResearchConceptsPrimary PCIPrimary percutaneous coronary interventionST-segment elevation resolutionMyocardial blush gradeAcute myocardial infarctionDiabetes mellitusMyocardial perfusionMyocardial infarctionIndependent predictorsGrade 3Late Angioplasty Complications (CADILLAC) trialTIMI flow grade 3Infarct-related arteryAbnormal myocardial perfusionPercutaneous coronary interventionAbciximab administrationControlled AbciximabPostprocedural ThrombolysisBlush gradePrimary angioplastyComplications TrialCoronary interventionReperfusion successMyocardial reperfusionPoor prognosisImpact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, Investigators F. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal Of Cardiology 2005, 95: 1-7. PMID: 15619385, DOI: 10.1016/j.amjcard.2004.08.054.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationAcute myocardial infarctionPrimary end pointDiabetic patientsNondiabetic patientsPrimary angioplastyDiabetes mellitusStent implantationMyocardial infarctionIschemic target vessel revascularizationEnd pointRoutine stent implantationAbciximab useComposite incidenceReperfusion modalityRoutine stentingAngiographic restenosisVessel revascularizationBalloon angioplastyImproved outcomesPatientsAngioplastyAbciximabDiabetesBeneficial effects
2004
Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention
Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, Leon MB, Dangas GD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. The American Journal Of Cardiology 2004, 94: 300-305. PMID: 15276092, DOI: 10.1016/j.amjcard.2004.04.023.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryCause of DeathChi-Square DistributionCohort StudiesCoronary DiseaseDiabetic AngiopathiesFemaleHumansKidney Failure, ChronicMaleMiddle AgedProbabilityPrognosisRenal DialysisRisk AssessmentSeverity of Illness IndexSex FactorsStatistics, NonparametricStentsSurvival AnalysisTreatment OutcomeConceptsChronic kidney diseasePercutaneous coronary interventionContrast-induced nephropathyPrognosis of patientsCoronary interventionRenal functionDiabetes mellitusKidney diseaseMortality rateImpact of CKDRole of CKDDe novo dialysisOutcomes of patientsHospital complicationsGastrointestinal bleedingNeurologic eventsFrequent complicationDiabetic patientsIndependent predictorsInsulin treatmentPatientsContrast mediumNephropathyDialysisMellitusFavorable effect of γ‐radiation for in‐stent restenosis: Effect of diabetes on angiographic and clinical outcomes
Iakovou I, Mehran R, Dangas G, Lansky AJ, Stone GW, Mintz GS, Aymong E, Ashby DT, Pichard AD, Satler LF, Kent K, Leon MB, Waksman R. Favorable effect of γ‐radiation for in‐stent restenosis: Effect of diabetes on angiographic and clinical outcomes. Catheterization And Cardiovascular Interventions 2004, 62: 303-307. PMID: 15224295, DOI: 10.1002/ccd.20070.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationDiabetes mellitusStent restenosisMajor adverse cardiac event ratesAdverse cardiac event ratesIn-Stent Restenosis TrialLower target lesion revascularizationMajor adverse cardiac eventsNon-DM patientsAdverse cardiac eventsCardiac event rateTreatment of ISREffect of diabetesSimilar procedural successGamma radiation therapyLesion revascularizationHospital outcomesRestenosis TrialVessel revascularizationCardiac eventsProcedural successClinical outcomesWashington RadiationVascular brachytherapyPatients